EGFR and neoplasm: Following approval by the FDA, the COBAS EGFR mutation test v2 (Roche) became the new proposed paradigm of treatment guidelines for EGFR T790M by testing cfDNA prior to tumor tissue, and has been applied in clinical practice [13].